CRISPR up­start Case­bia picks Sanofi vet Burns as new CEO; On the heels of a tri­al de­ba­cle, Opexa sheds staffers

Jim Burns, who had head­ed Sanofi’s R&D ops in Boston, is jump­ing ship to take the helm of Case­bia Ther­a­peu­tics, the $335 mil­lion gene edit­ing JV cre­at­ed by Bay­er and CRISPR Ther­a­peu­tics $CR­SP. Case­bia re­cent­ly inked a big lease in the heart of Kendall Square. “With ac­cess to cut­ting-edge gene-edit­ing CRISPR/Cas9 tech­nol­o­gy, pro­tein en­gi­neer­ing ex­per­tise, a strong fi­nan­cial foun­da­tion, and with Boston’s in­cred­i­ble net­work of tal­ent and part­ners, we have all the tools need­ed to cre­ate a po­ten­tial­ly trans­for­ma­tive new class of ther­a­pies for pa­tients,” Burns said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER